Citation for published version (APA):
Birchwood, M., Dunn, G., Meaden, A., Tarrier, N., Lewis, S., Wykes, T., ... Peters, E. (2018). The COMMAND trial of cognitive therapy to prevent harmful compliance with command hallucinations: Predictors of outcome and mediators of change. Psychological Medicine, 48(12), 1966-1974. https://doi.org/10.1017/S0033291717003488
The COMMAND trial of cognitive therapy to prevent harmful compliance with command hallucinations: predictors of outcome and mediators of change

Max Birchwood1, Graham Dunn2, Alan Meaden3, Nicholas Tarrier4, Shon Lewis5, Til Wykes6, Linda Davies7, Maria Michail8 and Emmanuelle Peters6

1Mental Health and Wellbeing, Warwick Medical School, University of Warwick, Coventry, UK; 2Centre for Biostatistics, Institute of Population Health, University of Manchester, Manchester, UK; 3Faculty of Health Science, Birmingham City University, Birmingham, UK; 4School of Psychological Science, University of Manchester, Manchester, UK; 5Division of Psychiatry, School of Medicine, University of Manchester, Manchester, UK; 6Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK; 7Centre for Health Economics – Institute of Population Health, University of Manchester, Manchester, UK and 8School of Psychology, University of Birmingham, Birmingham, UK

Background. Acting on harmful command hallucinations is a major clinical concern. Our COMMAND CBT trial approximately halved the rate of harmful compliance (OR = 0.45, 95% CI 0.23–0.88, p = 0.021). The focus of the therapy was a single mechanism, the power dimension of voice appraisal, was also significantly reduced. We hypothesised that voice power differential (between voice and voice hearer) was the mediator of the treatment effect.

Methods. The trial sample (n = 197) was used. A logistic regression model predicting 18-month compliance was used to identify predictors, and an exploratory principal component analysis (PCA) of baseline variables used as potential predictors (confounders) in their own right. Stata’s paramed command used to obtain estimates of the direct, indirect and total effects of treatment.

Results. Voice omnipotence was the best predictor although the PCA identified a highly predictive cognitive-affective dimension comprising: voices’ power, childhood trauma, depression and self-harm. In the mediation analysis, the indirect effect of treatment was fully explained by its effect on the hypothesised mediator: voice power differential.

Conclusion. Voice power and treatment allocation were the best predictors of harmful compliance up to 18 months; post-treatment, voice power differential measured at nine months was the mediator of the effect of treatment on compliance at 18 months.

Acting on delusions and commanding voices, remains a major concern for psychiatry with attendant societal and political concern, where members of the public are subject to apparently random acts of violence, even when they are well supported by services. Harm to self is an even greater risk linked to commanding voices (Birchwood et al. 2014). This is reflected in national policy documents, for example, the national mental health strategy in England aimed to reduce ‘avoidable harm’ to self or others (UK Department of Health, 2011). While drug treatment has improved, approaching 50% will continue to experience treatment-resistant symptoms or symptoms arising from non-adherence to drug regimes (Leucht et al. 2009). Auditory hallucinations (AH) rank among the most prominent of the treatment-resistant symptoms and among the most distressing and high risks of all are command hallucinations (Upthegrove et al. 2016). Command hallucinations are prevalent in people with schizophrenia and related disorders. A review by Shawyer et al. (2003) reported a median prevalence rate of 53% with a wide range from 18% to 89%, in a sample of adult psychiatric patients; of these, 48% stipulated harmful or dangerous actions. Among patients in medium secure units, compliance rises to 69% (Rogers et al. 2002). This rate appears significantly higher in the forensic population with 83% of voice hearers experiencing command hallucinations with criminal content (Beck-Sander et al. 1997). However, the link between the presence of command hallucinations and harm to self or others is not straightforward. In the Macarthur study (Appelbaum et al. 2000), no association was reported between the presence of delusions or command hallucinations and violence (GBH, assault and threats with a weapon). It appears to be the content of the individual’s thinking and how this reflects the dynamics of their relationship with the supposed persecutor who is commanding them, that is found to be predictive of harm to self and others (Beck-Sander et al. 1997; Bucci et al. 2013). Our cognitive model of ‘voices’ has clarified that it is not only the level of activity of voices, or indeed their content, that drives affect and behaviour, but the nature of the relationship with the personified voice (Chadwick & Birchwood, 1994; Birchwood et al. 2004; Connor & Birchwood, 2013); see review by...
Mawson et al. (2010). We showed that where the voice hearer believes the voice to have malevolent intent, and crucially to have the power to deliver the threat, this can motivate compliance or appeasement behaviour (Birchwood et al. 2004). These findings have been independently replicated in a forensic population (Fox et al. 2004). This framework informed the development of our targeted cognitive behaviour therapy (CBT) treatment designed to weaken and challenge a single mechanism, beliefs about voices’ power, thus enabling the individual to break free of the need to comply or appease and thereby reduce harmful compliance behaviour and distress (Byrne et al. 2006; Meaden et al. 2013). The effect of cognitive therapy for command hallucinations (CTCH) was tested in a full multi-centre trial of 197 individuals with a recent history of harmful compliance, involving harm to themselves or others. This group was observed to have a 46% rate of recurrence of harmful compliance within 18 months in the control group compared with 28% of those receiving CTCH [odds ratio = 0.45, 95% confidence interval (CI) 0.23–0.88, p = 0.021]. This was accompanied by a reduction in the perceived power of the voice (the estimated treatment effect common to both time points was –0.52 [95% CI –0.849 to –0.185], p = 0.002]. No differential impact on other secondary outcomes was observed.

In our main results paper (Birchwood et al. 2014) we highlighted two outstanding questions from our protocol (Birchwood et al. 2011), of theoretical and clinical importance. First, what are the key baseline predictors of outcome at 18 months? Here we are interested in whether it is voice beliefs, psychosis severity, demographic and historical factors, treatment allocation, or a combination of these, which predict further acts of harmful compliance; our preliminary study found voice power to be the best individual predictor (Bucci et al. 2013). Second, while these results were in line with predictions (changes in power and in compliance) we did not establish voice power as the mediator of change, as predicted by our model. This paper addresses each of these questions.

Method

Trial design

This was a single (rater) blind, prospective, pragmatic randomised controlled trial, using intention to treat to compare CTCH + Treatment as usual (TAU) with TAU alone. The trial recruited eligible participants from UK sites in Birmingham, Leicester, London and Manchester.

The trial was funded by the Medical Research Council (G0500965), was registered (ISRCTN62304114) and received ethical approval from the West Midlands Research Ethics Committee (06/MRE07/71). Full details on the design and trial findings can be found in the trial protocol (Birchwood et al. 2011) and primary publication (Birchwood et al. 2014).

Participants

A total of 197 of 242 eligible participants consented to the trial (81%), fulfilling the following criteria: (i) ICD – 10 schizophrenia, schizoaffective (F20, 22, 23, 25, 28, 29), or mood disorders (F32) (WHO, 2009), under care of a clinical team; (ii) age ≥16; (iii) history of command hallucinations of at least 6 months with recent (<9 months) history of harm to self, others or major social transgressions as a result of the commands; or harmful command hallucinations where the individual is distressed and appeasing the powerful voice and therefore at risk of full compliance. Exclusion criteria included: organic impairment or addictive disorder considered to be the primary diagnosis; insufficient command of the English language. The mean age of the sample was 37.4 (12.1; 16–64) and 113 (57%) male. Harmful compliance included harm to self (n = 119), others (42), kill self and/or other (53). All were in receipt of anti-psychotic medication.

The intervention and treatment as usual

CTCH is designed to weaken and change beliefs about voices’ power, thus enabling the individual to break free of the need to comply or appease and thereby reduce harmful compliance behaviour and distress. Our CTCH treatment protocol was developed by the first author and detailed in our casebook manuals (Byrne et al. 2006; Meaden et al. 2013). The primary aim of the therapy is to reduce the power differential between voice and voice hearer. The essence of the therapy is to test out the perceived power of the voice by examining evidence for: (a) the voice hearer’s perceived lack of control over voice activity, (b) the perceived omniscience of the voice (e.g. the apparent ability of the voice to predict the future) and (c) the perceived capacity of the voice to carry out its threats for non-compliance. CTCH was administered over a maximum period of 9 months. This includes a therapeutic window up to 25 sessions. TAU was provided by Community Mental Health Teams, Assertive Outreach and Early Intervention Teams. TAU including anti-psychotic medication was documented and did not differ between the groups.

Measures

Compliance

The level of compliance/resistance was assessed using the Voice Compliance Scale (VCS) (Addington et al. 1993) after: (a) conducting a thorough interview using the Cognitive Assessment of Voices schedule in order to obtain a detailed record of all voices as well as emotional and behavioural responses towards these voices; (b) interviewing and using information from at least one other informant (carers, care-coordinator). This yields specific behaviours which are classified as: neither appeasement nor compliant (1); symbolic appeasement, i.e. compliant with innocuous and/or harmless commands (2); actual appeasement, i.e. preparatory acts or gestures (3); partial compliance with at least one severe command (4); full compliance with at least one severe command (5). Twenty-nine of these were independently rated by MM for the presence v. absence of full compliance, with an overall Kappa of 0.73.

The primary outcome was the presence of full compliance (score 5) over the preceding nine months, with documented and independently verified behaviours. This was accordingly treated as a binary measure in the regression analyses.

Beliefs about voices

Power

The Voice Power Differential Scale (VPD-total) (Birchwood et al. 2004) was used to measure the perceived power differential between voice and voice hearer, which includes the following constructs: power, strength, confidence, respect, ability to inflict harm, superiority and knowledge. This scale has good internal reliability (Cronbach’s α = 0.85) with high 1-week re-test.
reliability ($r = 0.82$). The first item on the scale, the ‘pure’ power differential between voice and voice hearer, was analysed separately in keeping with our protocol and full trial. This item like the others in the scale is a bipolar construct on a five point scale (‘In relation to my voice I feel much more powerful … much less powerful’) and will be referred to as VPD-power.

**Omniscience**
The Personal Knowledge questionnaire/Omniscience scale (Birchwood et al. 2004) measured the voice hearer’s beliefs about the voice’s knowledge regarding personal information (e.g. ‘The voice knows everything about me and my past’).

**Voices’ intentions**
The Beliefs about Voices Questionnaire-Revised (BAVQ-R) (Chadwick et al. 2000) was used to assess key beliefs about voices’ omnipotence and intentions, whether benevolent or malevolent, as well as participants’ emotional and behavioural reactions towards their voices (resistance v. engagement). The scale has good test-retest ($r = 0.89$) and internal reliability (Cronbach’s $\alpha = 0.85$) and is widely used in hallucinations research.

**Auditory hallucinations**
Voices were assessed using the Psychotic Symptoms Rating Scales (PSYRATS) (Haddock et al. 1999) and specifically the section about AH. The scale benefits from excellent psychometric properties with inter-rater reliability for the AH section ranging between 0.78 and 1.0.

**Depression, hopelessness & suicidal ideation**
The Calgary Depression Rating Scale for Schizophrenia (Addington et al. 1993) is a widely used nine-item observer-rated measure specifically designed for schizophrenia, minimising contamination by negative symptoms and the extrapyramidal side effects of neuroleptics. The Beck Hopelessness Scale (Beck, 1988) was used to assess three aspects of hopelessness: feelings about the future, loss of motivation and expectations and the disclosure of negative symptoms and the extrapyramidal side effects of neuroleptics. The Beck Scale for Suicidal Ideation allows for a thorough examination of suicidal intent.

**Psychotic symptoms**
The Positive and Negative Syndrome Scale (PANSS) (Kay et al. 1987) includes scales of positive symptoms, negative symptoms and general psychopathology and is used widely in schizophrenia research.

**Childhood neglect and trauma**
The Childhood Trauma Questionnaire (Bernstein and Fink, 1988) is a widely used 28-item self-report inventory measuring retrospectively experiences of childhood abuse and neglect. It consists of five subscales: emotional abuse, physical abuse, sexual abuse, emotional neglect and physical neglect, reflecting, therefore, a broad range of early adverse experiences. The CTQ has proved to have high internal reliability with $\alpha$-value ranging from 0.66 for the physical abuse subscale to 0.92 for the sexual abuse subscale. It has also demonstrated good test–retest reliability ranging from 0.79 to 0.86 for the five subscales over an average period of four months.

**Statistical methods**

**Baseline predictors of 18-month compliance**
All statistical analyses were carried out using Stata version 13 (Stata Corporation, 2013). Thirty pre-randomisation, baseline predictor variables were considered including voice beliefs (13 variables), psychosis severity (four variables), parental abuse and neglect (five variables), demographic and historical factors (five variables) and effective functioning (three variables) in addition to treatment allocation and centre membership. In order to avoid confusion, readers should note that psychologists’ term ‘predictive variable’ does not have the same meaning as ‘predictive marker’ as used in the personalised medicine literature (Dunn et al. 2013). The latter is equivalent to the psychologists’ ‘moderator’ (a treatment effect modifier). Here, we are dealing with potential predictors that are assumed to have the same effect in both arms of the trial. The starting point (as in the initially reported evaluation of treatment efficacy (Birchwood et al. 2014)) was a logistic regression model to predict 18-month full compliance by treatment allocation, centre membership (two binary dummy variables, C1 and C2) and baseline compliance on the VCS (with three levels). Centre membership was kept in all of the statistical models because of the trial design: randomisation taking place within (or stratified by) centre. Baseline compliance was not a statistically-significant predictor and was then dropped from the model. So, starting with a model containing the effects of treatment and centre membership, each of the 30 potential predictors were added in turn, and their predictive effects and associated statistical significance assessed using the likelihood ratio-based chi-square statistics. The effects of employment and marital status were not assessed since there was too little variation in these measures. The best (most statistically significant) predictor was kept in a new baseline model and each of the remaining 29 potential predictors again added in turn, and their predictive ability determined. This forward selection procedure was accompanied by a corresponding backward elimination, starting with a model with all potential predictors and proceeding until deletion of a potential predictor led to a statistically significant worsening in goodness-of-fit (again, indicated by the change in chi-square).

As a result of the above analyses, a selection of the potential predictors was made, based on their ability to predict outcome over and above treatment and centre membership. These baseline predictors were likely to be fairly highly correlated and their correlation matrix was then subjected to an exploratory principal components analysis, and the principal components extracted and saved to be used as potential predictors in their own right.

**Mediation analysis**
Here, again, all initial statistical analyses were carried out using Stata version 13 (StataCorp, 2013). The analyses are aimed at evaluating the potential mediating role of voice power (VPD) (either the total score or the power differential item) in the treatment effect on compliance at 18 months. The main potential threat to the validity of the findings is confounding of the effect of the mediator (VPD) on outcome (Compliance), even though the treatment itself has been randomised. Another threat (or source of bias) is measurement error in the putative mediator. First, we concentrated on adjustment for confounding. The logistic regression model for the outcome (18-month compliance) initially included the effects of treatment and the following covariates: centre membership (two binary dummy variables, C1 and C2) the first principal
component score (PCA1) obtained from the above analysis of potential predictors (defined in the ‘Results’ section). This produced a revised intention-to-treat effect. PCA1 was included because it is likely to be an important confounder of the effect of the putative mediator on the clinical outcome – being a powerful predictor of both the VPD scores and 18-month compliance. Linear regression models for the putative mediator (VPD-total score at 9 months or the VPD-power item) included the effects of treatment and the same set of covariates. Finally, the second pair of logistic regression models for 18-month compliance was fitted, containing the same variables as the first ones above but, with the addition of the putative mediators: the 9-month values for either the VPD total score or the VPD power item. The latter models were also fitted using Stata’s `paramed` command (Emsley et al. 2014; Dunn et al. 2015): in order to obtain estimates of the direct, indirect and total effects of treatment. Standard errors and 95% CI were used via the use of bias-corrected bootstrap methods (each based on 1000 bootstrapped samples) – see (Efron and Tibshirani, 1993). Readers should be aware that the total effects of treatment will not correspond exactly to the estimate reported in the original trial report (Birchwood et al. 2014). Hence, the phrase ‘revised intention-to-treat effect’ as used above. This is not a sign of disagreement but follows from the fact that treatment effects are being estimated using odds ratios, conditional on the other covariates in the model. As the additional covariates change so does the definition of the treatment effect (unlike the case when using linear regression/ANCOVA models for quantitative outcomes).

Finally, we evaluated mediation models in which 9- and 18-month measurements of the VPD-total score (or the VPD-power item) were assumed to be replicate measurements of an underlying latent variable (factor – labelled VPD-Total in the case of the total score, and VPD-Power for the power item). The latent factor was used to address measurement error. The replicate measurements for each of the two factors were assumed to have zero relative bias and the same measurement error variances (precision – i.e. they were assumed to be parallel measures). We would, of course, expect the precision of the power item to be considerably lower than that for the total score. This simple factor analysis model was then fitted simultaneously with a logistic regression model to predict 18-month compliance using the structural equations program Mplus version 7.0 (Muthen and Muthen, 2012). The covariates in the latter were treatment, centre membership (C1 and C2), PCA1 and the VPD factor as the putative mediator (either the VPDT or VPD).

Results

Intention to treat analysis

The evaluation of the primary outcome was through an intention-to-treat (ITT) analysis using a logistic regression, allowing for centre membership and severity of command hallucinations at baseline. This is detailed in our primary publication (1) but in summary, 197 participants (see Table 1) were randomly assigned (98 to CTCH + TAU and 99 to TAU), representing 81.4% of eligible individuals. At 18 months, 46% of the TAU participants fully complied compared to 28% of those receiving CTCH + TAU (odds ratio = 0.45, 95% CI 0.23–0.88, p = 0.021). A summary of outcome and mediator measures over time by randomisation group is shown in Table 2. The estimate of the treatment effect common to both follow-up points was an odds ratio of 0.57 (95% CI 0.33–0.98, p = 0.042); that for 18-month compliance was an odds ratio of 0.45, 95% CI 0.23–0.88, p = 0.021. The total estimated treatment effect for VPD-total common to both time points was −1.819 (95% CI −3.457 to −0.181, p = 0.03). For the VPD-power differential item, the estimated treatment effect for both time-points was −0.52 (−0.849 to −0.185, p = 0.002).

Baseline predictors of 18-month compliance

In addition to the effect of treatment there were also centre differences in 18-month compliance; however, once other baseline predictors were added to the model these centre effects were very variable. When each of the potential predictors (Table 3) were added to the logistic model, one at a time, 11 were found to have a statistically-significant effect, using the uncorrected nominal significance level of 0.05. The results are shown in Table 4, ranked according to their associated p value. The best predictor was BAVQ Omnipotence with stronger beliefs linked to compliance (p = 0.005). When the latter was kept in the model and the other potential predictors were then added, one at a time, the only one to significantly add to the prediction was CTQ emotional abuse (p = 0.045). Bearing in mind the repeated testing or multiplicity problem (i.e. family-wise error rates), the latter is almost certainly of no consequence. A backwards elimination confirmed the above results, yielding a model that contained treatment, centre and BAVQ Omnipotence.

In a further set of analyses, a principal component analysis was carried out on the correlation matrix for the eleven statistically significant predictors in Table 4. The first four principal components had eigenvalues of 3.690, 1.652, 1.137 and 1.034, respectively (explaining 68% of the total variation). Returning to the predictive models, the only principal component to predict 18-month compliance was the first one (which was essentially the average, after standardisation, of the eleven selected baseline variables). The estimated odds ratio for an increase of one unit of the 1st principal component was 1.503 (s.e. 0.165; p value <0.001; 95% CI 1.211–1.865). The estimated odds ratio for the treatment effect in this model was 0.476 (s.e. 0.179; p value 0.048; 95% CI 0.228–0.993). Manchester had lower levels of 18-month compliance than Birmingham/Leicester (odds ratio 0.329; s.e. 0.156; p value 0.019; 95% CI 0.130–0.834), as did London (odds ratio 0.300; s.e. 0.135; p value 0.008; 95% CI 0.124–0.727). There was no suggestion that the treatment effect was in anyway moderated by the level of the baseline first

| Gender (male): | 113 (57%) |
| Site: Birmingham/Leicester | 87 (44%) |
| Manchester | 48 (24%) |
| London | 62 (31%) |
| Ethnicity: non-white | 68 (35%) |
| Employment: Employed | 16 (32%) |
| Unemployed | 144 (74%) |
| Other | 19 (10%) |
| Cohabitating: yes | 20 (10%) |

Table 1. Description of COMAND trial sample at baseline
The eleven baseline predictor variables given equal weight in the PCA 1st principal component were: BAVQ Omnipotence and Malevolence scales, CTQ Physical abuse and Emotional abuse scales, CDSS (Depression), VPD Voice power (total), BSI (Suicidal thinking) PSYRATS voices (total), CTQ Emotional neglect, PKQ (Omniscience) and PANSS Positive total. These encompass beliefs about voices power and threat; childhood trauma; depression and self-harm all of which have featured as key

Table 2. Summary of outcome and mediator measures over time by randomisation group

|                       | Baseline | 9 months | 18 months |
|------------------------|----------|----------|-----------|
| **Full compliance**    |          |          |           |
| CTCH                   | 84 (86%) | 41 (48%) | 22 (28%)  |
| TAU                    | 81 (81%) | 49 (55%) | 39 (46%)  |
| **VPD power: mean (s.d.)** |          |          |           |
| CTCH                   | 3.9 (1.2) n = 97 | 2.8 (1.2) n = 87 | 2.8 (1.3) n = 76 |
| TAU                    | 4.0 (1.0) n = 98 | 3.3 (1.4) n = 86 | 3.2 (1.4) n = 81 |
| **VPD total: mean (s.d.)** |          |          |           |
| CTCH                   | 26.5 (5.5) n = 95 | 21.3 (5.9) n = 87 | 22.4 (6.2) n = 75 |
| TAU                    | 27.4 (4.6) n = 96 | 24.0 (6.4) n = 85 | 23.4 (6.9) n = 81 |

VPD, Voice power differential; CTCH, Cognitive therapy for command hallucinations; TAU, Treatment as usual.

Table 3. Baseline predictors: summary statistics

| Variable               | Observed | Mean       | s.d.    | Min | Max |
|------------------------|----------|------------|---------|-----|-----|
| Age at onset           | 178      | 22.140     | 10.562  | 5   | 63  |
| PANSS Positive         | 197      | 19.381     | 4.865   | 10  | 33  |
| PANSS Negative         | 195      | 16.021     | 6.293   | 7   | 34  |
| PANSS General          | 195      | 36.374     | 8.602   | 17  | 71  |
| PANSS Total            | 195      | 71.733     | 16.559  | 38  | 132 |
| CDSS (Depression)      | 197      | 12.091     | 6.008   | 0   | 27  |
| BHS (Hopelessness)     | 193      | 10.720     | 5.395   | 1   | 20  |
| BSI (Suicidal thinking)| 196      | 9.908      | 9.372   | 0   | 34  |
| PKQ (Omniscience)      | 197      | 10.594     | 3.218   | 1   | 15  |
| VPD (Voice power)      | 195      | 3.923      | 1.103   | 1   | 5   |
| VPD total              | 191      | 26.953     | 5.054   | 9   | 35  |
| PSYRATS total          | 194      | 32.629     | 4.400   | 18  | 41  |
| BAVQ Malevolence       | 197      | 13.051     | 4.332   | 2   | 18  |
| BAVQ Benevolence       | 196      | 3.367      | 3.989   | 0   | 15  |
| BAVQ Omnipotence       | 197      | 13.487     | 3.748   | 0   | 18  |
| BAVQ Resistance (total)| 197      | 21.381     | 4.856   | 5   | 27  |
| BAVQ Resistance (E)    | 197      | 9.853      | 2.302   | 1   | 12  |
| BAVQ Resistance (B)    | 197      | 11.528     | 3.599   | 0   | 15  |
| BAVQ Engagement (total)| 197      | 5.061      | 4.919   | 0   | 21  |
| BAVQ Engagement (E)    | 197      | 1.990      | 2.837   | 0   | 12  |
| BAVQ Engagement (B)    | 197      | 3.071      | 2.874   | 0   | 12  |
| CTQ (Emotional abuse)  | 192      | 14.135     | 6.677   | 5   | 25  |
| CTQ (Physical abuse)   | 190      | 10.484     | 5.818   | 5   | 25  |
| CTQ (Sexual abuse)     | 190      | 10.326     | 7.411   | 5   | 25  |
| CTQ, Emotional neglect | 192      | 12.995     | 6.437   | 5   | 25  |
| CTQ (Physical neglect) | 192      | 9.547      | 4.945   | 5   | 25  |

VPD, Voice power differential; BAVQ, Beliefs about voices questionnaire; CTQ, Childhood trauma questionnaire; PANSS, Positive and negative syndrome scale; BSI, Beck suicide inventory; BHS, Beck hopelessness scale; CDSS, Calgary depression scale for schizophrenia; PKQ, Personal knowledge questionnaire; PSYRATS, Psychosis rating scales.
Mediation analysis

It is hypothesised that CTCH will give the patient more power over the voice and the ability to resist its commands and so make them less likely to comply. The power differential between the voice and the patient was measured by the VPD total. The power item is a 1–5 rating where a score of one indicates power with the individual and 5 indicates that the power lies with the voice. An improvement would therefore be indicated by a reduction in the total VPD-total and VPD-power items. We are hypothesising that VPD power at 9 months mediates the impact of treatment on compliance at 18 months. These hypotheses are supported by the results provided below.

Results of fitting predictive models for 18-month compliance, and for 9-month VPD-total and VPD-power scores, are given in Table 5a–c. These simply confirm the original ITT analyses. Note that both centre membership and PCA1 are included in all models evaluating the effect of the mediator on outcome. The next step involves the inclusion of the putative mediators in the outcome model. These results are given in Table 5d and e. In Table 5d, it can be seen that the effect of the proposed mediator is highly statistically significant (although the estimated odds ratio is very close to unity, it should be remembered that this is the effect of increasing the 9-month VPD total by a single unit). The effect of treatment not explained by the 9-month VPD-total has an estimate (odds ratio 0.526) that is closer to the null than that given in Table 5. The corresponding direct effect is not significantly different from unity – it should be remembered that this is the effect of increasing the mediator at the value it would have had in the control condition to that which it has under treatment, whilst setting Treatment = 1 (i.e. everyone receives the intervention). The corresponding natural direct effect (nde) is the effect of receiving treatment (changing Treatment from 0 to 1) whilst fixing the mediator at the value it would have had under the control condition (Treatment = 0). Using 9-month VPD total as the mediator, we obtain the following estimates: te = 0.402 (95% CI 0.153–0.998); nie = 0.763 (95% CI 0.456–0.939); nde = 0.526 (95% CI 0.215–1.503). Using 9-month VPD power we obtain: te = 0.410 (95% CI 0.166–1.107); nie = 0.889 (95% CI 0.603–1.005); nde = 0.461 (95% CI 0.191–1.193). Note that the estimated direct effects are exactly the same as those reported in Table 5d and e, respectively, but with wider confidence intervals. The estimated natural indirect effects (both odds ratios less than unity) correspond to that component of the treatment effect that is fully explained by its effect on the mediator. We conclude that 9-month VPD total is a mediator of the effect of treatment on 18-month compliance, but it is difficult to establish whether all of the treatment effects is explained by it (the fact that the corresponding direct effect is not significantly different from unity does not mean that it actually is unity – we cannot rule out lower values). The estimated natural indirect effect for 9-month VPD power, however, is not statistically significantly different from unity (the 95% CI straddles the value of 1) and conclude that we have not been able to demonstrate that VPD power is a mediator.

Finally, the latent variable model evaluating the mediating effect of VPD-total factor led to an estimated effect of the mediator on the outcome of 1.113 (95% CI 0.995–1.245), consistent with the estimate in Table 5d, but less precise. Measurement error does not appear to be a major source of bias, here. The corresponding result for the VPD power factor was 1.381 (95% CI 1.290–1.503). Again, measurement error does not appear to be a major source of bias, but the estimates are so imprecise that we stick with the conclusion that we have not been able to demonstrate that VPD power is a mediator.

Discussion

The COMMAND trial tested the effectiveness of our targeted CBT to reduce the risk of harmful compliance with commanding voices in those who had complied within the previous nine months. The trial showed a large and significant reduction in both the compliance and the central target of the therapy, beliefs about the power of voices, in particular, the difference in power between voice and voice hearer. In this paper, we addressed two central and related questions that are at the heart of the cognitive model and the CBT: to what degree does voice power and omnipotence predict compliance at final follow-up and did it act as the mediator of change? The logistical regression procedure identified eleven baseline predictors of outcome, over and above treatment and centre membership. The stepwise elimination routine identified BAVQ voice omnipotence as the best individual predictor; the other baseline predictors did not seem to have any predictive ability not explained by BAVQ omnipotence.

Table 4. Significant individual predictors of 18-month compliance

| Predictor | Odds ratio | s.e. | p value | 95% CI |
|-----------|------------|------|---------|--------|
| BAVQ Omnipotence | 1.163 | 0.063 | 0.005 | 1.046–1.292 |
| BAVQ Malevolence | 1.122 | 0.051 | 0.011 | 1.027–1.226 |
| CTQ (Physical abuse) | 1.076 | 0.032 | 0.013 | 1.015–1.139 |
| CTQ (Emotional abuse) | 1.071 | 0.030 | 0.014 | 1.014–1.131 |
| CDSS (Depression) | 1.074 | 0.032 | 0.015 | 1.014–1.138 |
| VPD Voice power (total) | 1.099 | 0.043 | 0.017 | 1.017–1.188 |
| BSI (Suicidal thinking) | 1.046 | 0.020 | 0.018 | 1.008–1.085 |
| PSYRATS (voices) total | 1.105 | 0.047 | 0.019 | 1.017–1.201 |
| CTQ (Emotional neglect) | 1.065 | 0.030 | 0.024 | 1.008–1.125 |
| PKQ (Omnipotence) | 1.141 | 0.066 | 0.024 | 1.018–1.279 |
| PANNS Positive | 1.074 | 0.038 | 0.044 | 1.002–1.151 |

VPD, Voice power differential; BAVQ, Beliefs about voices questionnaire; CTQ, Childhood trauma questionnaire; PANNS, Positive and negative syndrome scale; BSI, Beck suicide inventory; CDSS, Calgary depression scale for schizophrenia; PKQ, Personal knowledge questionnaire; PSYRATS, Psychosis rating scales.
These baseline predictors were however highly correlated and their correlation matrix was then subjected to an exploratory principal components analysis; the principal components extracted were saved to be used as potential predictors in their own right. The eleven predictors loaded equally on the first principal component, comprising beliefs about voices power and threat; childhood trauma; depression, hopelessness and suicidal thinking all of which are the key features of our cognitive model of voices. We describe this as the cognitive-affective dimension of voice hearing and it is this that strongly predicted 18-month compliance. In testing the mediating effect of voice power differential, the first principal component was an important variable to include as a confounder in the mediation model, confirmed by its highly significant prediction of 9-month compliance.

In the subsequent mediation analysis, controlling for any confounding effect of centre and PCA1, we found that the estimated natural indirect effects of treatment corresponded to that component of the treatment effect that is fully explained by its effect on the hypothesised mediator: 9-month voice power differential. There were no direct effects of treatment once the effect on the mediator was accounted for. We conclude that 9-month VPD-total was a mediator of the effect of treatment on 18-month compliance. While we cannot rule out a direct effect of treatment on outcome, it is very difficult to obtain a precise estimate of this residual (unmediated) treatment effect; if there were comparable trials it would be an ideal candidate for an IPD (individual patient data) meta-analysis.

We have been able to demonstrate the mediating role of VPD-total, but have failed to demonstrate the same for VPD

| Table 5. Revised intention-to-treat (ITT) estimates, together with the effects of proposed mediators. |
|-----------------------------------------------|----------------|----------------|----------------|
| (a) 18-month compliance: ITT                  | Covariate      | Odds ratio    | p-value        | 95% CI         |
| Treatment                                    | 0.476          | 0.048         | 0.228-0.993    |
| C1                                           | 0.329          | 0.019         | 0.130-0.834    |
| C2                                           | 0.300          | 0.008         | 0.124-0.727    |
| PCA1                                         | 1.503          | <0.001        | 1.212-1.865    |
| (b) 9-month VPD total: ITT                    | Covariate      | Coef.         | p-value        | 95% CI         |
| Treatment                                    | −2.884         | 0.002         | −4.720 to −1.048 |
| C1                                           | −2.040         | 0.079         | −4.321 to 0.241 |
| C2                                           | −0.349         | 0.755         | −2.552 to 1.855 |
| PCA1                                         | 0.999          | <0.001        | 0.505-1.493    |
| (c) 9-month VPD power: ITT                    | Covariate      | Coef.         | p-value        | 95% CI         |
| Treatment                                    | −0.545         | 0.006         | −0.933 to −0.157 |
| C1                                           | −0.409         | 0.096         | −0.891 to 0.073 |
| C2                                           | −0.143         | 0.544         | −0.609 to 0.322 |
| PCA1                                         | 0.131          | 0.014         | 0.027-0.236    |
| (d) 18-month compliance with 9-month VPD total as a mediator | Covariate      | Odds ratio    | p-value        | 95% CI         |
| Treatment                                    | 0.526          | 0.116         | 0.236-1.173    |
| 9-m VPD total                                | 1.098          | 0.009         | 1.023-1.179    |
| C1                                           | 0.278          | 0.012         | 0.102-0.752    |
| C2                                           | 0.213          | 0.002         | 0.080-0.571    |
| PCA1                                         | 1.457          | 0.002         | 1.146-1.852    |
| (e) 18-month compliance with 9-month VPD power as a mediator | Covariate      | Odds ratio    | p-value        | 95% CI         |
| Treatment                                    | 0.461          | 0.054         | 0.210-1.012    |
| 9-m VPD power                                | 1.242          | 0.178         | 0.906-1.701    |
| C1                                           | 0.260          | 0.007         | 0.097-0.698    |
| C2                                           | 0.224          | 0.002         | 0.086-0.583    |
| PCA1                                         | 1.524          | <0.001        | 1.210-1.921    |

PCA1, Principal component 1; VPD, Voice power differential.
power item. This may be a sample size (statistical power) problem arising from a measure that contains considerable error variance. We cannot rule out a direct effect of treatment on outcome, and it is very difficult to obtain a precise estimate of this residual (unmediated) treatment effect.

Strengths and limitations

This trial mediation analysis has many strengths that lend confidence to the findings. This was a carefully designed and implemented RCT specifically targeted on voice power to achieve change in compliance with command hallucinations, and with a corresponding a priori hypothesis that voice power was the mediator. We employed a large sample size of a complex and difficult to recruit group, with a high rate of follow-up in both groups (83%). We made a careful search and allowance for predictors that could be used for confounder adjustment in the mediation models. Similarly, a careful check was made for the sensitivity of the results to measurement errors in the mediators. The prediction analysis was based on a prior hypothesis based on our cognitive model and on evidence from a preliminary study showing that voice power was the principal predictor of 9-month compliance (Bucci et al. 2013).

There are some caveats. First, although the data support the view that the effect of treatment on compliance is mediated by voice power differential (VPD-total) there is insufficient power to confidently rule out any possibility of some effect of treatment not mediated in this way (i.e. we cannot exclude a direct effect of treatment, including non-specific on compliance). Second, the trial did not find a differential impact of treatment on distress linked to voices (distress declined in both groups). Our previous cross-sectional and prospective work had led us to predict a treatment effect on voice-related distress, but this was not found, meaning we were unable to conduct a mediation analysis on this variable (though distress was a secondary outcome). Finally, there may be other methods of enhancing the power of the voice hearer: ‘avatar therapy’ (Leff et al. 2013) is rooted in our cognitive model and uses facsimile of voices to develop control and enhance power; similarly ‘relating’ therapy (Hayward et al. 2016) involves the rehearsal of assertive approaches to relating to the voice and to another significant problematic relationship.

We can conclude that the treatment effect in this trial was mediated by voice power but we cannot rule out the influence of other, for example, non-specific effects of the therapy, that could account for its impact.

Implications

This trial mediation analysis brings to full circle our influential cognitive model we formulated over 20 years ago (Chadwick & Birchwood, 1994). We argue that it provides convincing evidence that in relation to harmful behaviour at least, the perceived power of voices to threaten the individual, relative to the perceived power of the individual to challenge and mitigate this threat (power differential), is a strong and malleable influence on voice-related behaviour. Had the mediation analysis not supported the role of voice power, this would have questioned the foundation of the therapy in its focus on voice power differential and raised questions about other active agents, for example, demand characteristics of the trial, a placebo effect or bias. On the contrary, the mediation analysis supports the clinical model and opens the door for further research to understand the development of these appraisals as an interpersonal phenomenon and to explore the clinical model and its applicability to the generality of distressed voice hearers and to other symptoms where these appraisals are active, particularly persecutory delusions. Research is needed to augment this approach with methods to further reduce distress; in our structural equation model of voice distress (Birchwood et al. 2004) we identified that generalised subordination to others and depression appeared to be powerful drivers of distress in the relationship with voices and these may be targets for intervention for lasting change in voice distress. For the clinician working with individuals with harmful voices, assessment should include the perceived power of the voice relative to the individual, the sources of voice power and those of the voice hearer. We have documented the majority of cases (Byrne et al. 2006; Meaden et al. 2013) in the trial and pilot for the interested clinician. We have argued (Birchwood, 2015) that the next generation of CBtP should focus not on complex packages of care, where the mechanisms are unclear and the ability of the intervention to modify them is lost in the scattershot; rather we offer this paradigm of theoretical development, leading to targeted intervention focused on the mechanism of interest, as the path most likely to maximise clinical effectiveness of the next generation of cognitive therapy for psychosis.

Acknowledgements. Professor Helen Lester our colleague and co-author sadly died before the completion and publication of this paper.

We acknowledge the support of the NIHR Mental Health Research Network in recruiting participants; the trial steering committee (chair Prof Elizabeth Kuipers) and the Data Monitoring and Ethics Committee (chair Professor Andrew Gumley), for their assistance in setting up, conducting and monitoring the trial. We would like to thank the clinical teams and service users for their continuing support and participation in the trial. We would also like to acknowledge the work of the researchers and therapists involved in the trial. Professor Birchwood was part-funded by the National Institute for Health Research (NIHR) through the Collaborations for Leadership in Applied Health Research and Care for the West Midlands (CLAHRC-WM). The views expressed in this publication are not necessarily those of the NIHR, the Department of Health, the University of Warwick. Emmanuelle Peters and Til Wykes acknowledge support from the NIHR Biomedical Research Centre for Mental Health at King’s Health Partners, London UK. The trial was funded by the Medical Research Council (G0500965) and was registered (ISRCTN62304114).

Declaration of Interest. None.

Contributors. MB developed the model and hypotheses and GD designed and undertook the statistical analyses. The trial was designed by MB, EP, SL, TW, NT, LD, HL and GD. The study was administered by MB, MM, AM, EP, NT and SL. The trial manager was MM. CTCH was developed by MB. CTCH training was designed and led by MB and AM and AM led the supervision process. All authors contributed to the interpretation of the data, the writing of the paper and approved the final manuscript. MB had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Ethical standards. The trial received ethical approval from the West Midlands Research Ethics Committee (06/MRE/07/71). Full details on the design and trial findings can be found in the trial protocol (Birchwood et al. 2011) and primary publication (Birchwood et al. 2014).

References

Addington D, Addington J and Matickatayndale E (1993) Assessing depression in schizophrenia – the calgary depression scale. British Journal of Psychiatry 163, 39–44.
Appelbaum PS, Robbins PC and Monahan J (2000) Violence and delusions: data from the MacArthur violence risk assessment study. *American Journal of Psychiatry* **157**, 566–572.

Beck AT. (1988) *The Beck Hopelessness Scale*. New York: The Psychological Corporation.

Beck-Sander A, Birchwood M and Chadwick P (1997) Acting on command hallucinations: a cognitive approach. *British Journal of Clinical Psychology* **36**(Pt 1), 139–148.

Bernstein D and Fink M. (1988) *Childhood Trauma Questionnaire*. A Retrospective Self-Report Manual. San Antonio, TX: The Psychological Corporation.

Birchwood M. (2015) Knitting up the ravelled sleeve of care: sleep and psychosis. *Lancet Psychiatry* **2**, 950–951.

Birchwood M, Gilbert P, Gilbert J, Trower P, Meaden A, Hay J, et al. (2004) Interpersonal and role-related schema influence the relationship with the dominant ‘voice’ in schizophrenia: a comparison of three models. *Psychological Medicine* **34**, 1571–1580.

Birchwood M, Michail M, Meaden A, Tarrier N, Lewis S, Wykes T, et al. (2014) Cognitive behaviour therapy to prevent harmful compliance with command hallucinations (COMMAND): a randomised controlled trial. *Lancet Psychiatry* **1**, 23–33.

Birchwood M, Peters E, Tarrier N, Dunn G, Lewis S, Wykes T, et al. (2011) A multi-centre, randomised controlled trial of cognitive therapy to prevent harmful compliance with command hallucinations. *BMC Psychiatry* **11**, 135.

Bucci S, Birchwood M, Twist L, Tarrier N, Emsley R and Haddock G (2013) Predicting compliance with command hallucinations: anger, impulsivity and appraisals of voices’ power and intent. *Schizophrenia Research* **147**, 163–168.

Byrne S, Birchwood M, Trower P and Meaden A. (2006) *A Casebook of Cognitive Behaviour Therapy for Command Hallucinations: A Social Rank Theory Approach*. London & New York: Routledge.

Chadwick P and Birchwood M (1994) The omnipotence of voices. A cognitive approach to auditory hallucinations. *British Journal of Psychiatry* **164**, 190–201.

Chadwick P, Lees S and Birchwood M (2000) The revised Beliefs About Voices Questionnaire (BAVQ-R). *British Journal of Psychiatry* **177**, 229–232.

Connor C and Birchwood M (2013) Power and perceived expression of voices: their impact on depression and suicidal thinking in those who hear voices. *Clinical Psychology & Psychotherapy* **20**, 199–205.

Department of Health (2011) *No Health without Mental Health, a Cross-Government Mental Health Outcomes Strategy for People of All Ages*. UK: Department of Health.

Dunn G, Emsley R, Liu H, and Landau S. (2013) Integrating biomarker information within trials to evaluate treatment mechanisms and efficacy for personalised medicine. *Clinical Trials* **10**, 709–719.

Dunn G, Emsley R, Liu HH, Landau S, Green J, White I, et al. (2015) Evaluation and validation of social and psychological markers in randomised trials of complex interventions in mental health: a methodological research programme. *Health Technology Assessment* **19**, 1–115.

Efron B and Tibshirani RJ. (1993) *An Introduction to the Bootstrap*. London: Chapman & Hall.

Emsley R, Li H, Dunn G, Valer L and VanderWeel TJ (2014) PARAMED: A Command to Perform Causal Mediation Analysis Using Parametric Models: Technical Report. Stata Corporation. Stata Version 13. College Station, TX: Stata Corporation, 2013.

Fox JRE, Gray NS and Lewis H (2004) Factors determining compliance with command hallucinations with violent content: the role of social rank, perceived power of the voice and voice malevolence. *Journal of Forensic Psychiatry & Psychology* **15**, 511–531.

Haddock G, McCarron J, Tarrier N and Faragher EB (1999) Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS). *Psychological Medicine* **29**, 879–889.

Hayward M., Jones AM, Bogen-Johnston L, Thomas N, Strauss C (2016) Relating Therapy for distressing auditory hallucinations: a pilot randomized controlled trial. *Schizophrenia Research* **183**, 137–142.

Kay SR, Fiszbein A and Opler LA (1987) The positive and negative syndrome scale (panss) for schizophrenia. *Schizophrenia Bulletin* **13**, 261–276.

Leff J, Williams G, Huckvale M, Arbuthnot M and Leff A (2013) Computer-assisted therapy for medication-resistant auditory hallucinations: proof-of-concept study. *British Journal of Psychiatry* **202**, 428–433.

Leucht S, Arber D, Engel RR, Kissling W and Davis JM (2009) How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. *Molecular Psychiatry* **14**, 429–447.

Mawson A, Cohen K and Berry K (2010) Reviewing evidence for the cognitive model of auditory hallucinations: the relationship between cognitive voice appraisals and distress during psychosis. *Clinical Psychology Review* **30**, 248–258.

Muthen LK and Muthen BO (2012) *Mplus User’s Guide*. Los Angeles, CA: Muthen & Muthen.

Meaden A, Keen N, Aston R, Barton K and Bucci S (2013) *Cognitive Therapy for Command Hallucinations: An Advanced Practical Companion*. Hove: Routledge.

Rogers P, Watt A, Gray NS, MacColloch M and Gournay K (2002) Content of command hallucinations predicts self-harm but not violence in a medium secure unit. *Journal of Forensic Psychiatry* **13**, 251–262.

Shawyer F, Mackinnon A, Farhall J, Trauer T and Copolov D (2003) Command hallucinations and violence: implications for detention and treatment. *Psychiatry, Psychological Law* **10**, 97–107.

Upthegrove R, Broome MR, Caldwell K, Ives J, Oyebode F and Wood SJ (2016) Understanding auditory verbal hallucinations: a systematic review of current evidence. *Acta Psychiatrica Scandinavica* **133**, 352–367.

World Health Organisation (2009) *The ICD-10 Classification of Mental and Behavioural Disorders*. Geneva: World Health Organisation, 2009.